1. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T,
Hashiguchi S, Ichinose M, Bangham CR, Izumo S, Osame M: Analysis of
HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic
HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J
Neurovirol 1998, 4:586-593.
2. Bangham CRM, Meekings K, Toulza F, Nejmeddine M, Majorovits E,
Asquith B, Taylor GP: The immune control of HTLV-1 infection: selection
forces and dynamics. Frontiers in Bioscience 2009, 14:2889-2903.
3. Goon PK, Hanon E, Igakura T, Tanaka Y, Weber JN, Taylor GP, Bangham CR:
High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and
Tax proteins in patients with HTLV-1-associated myelopathy/tropical
spastic paraparesis. Blood 2002, 99:3335-3341.
4. Goon PK, Igakura T, Hanon E, Mosley AJ, Asquith B, Gould KG, Taylor GP,
Weber JN, Bangham CR: High circulating frequencies of tumor necrosis
factor alpha- and interleukin-2-secreting human T-lymphotropic virus
type 1 (HTLV-1)-specific CD4+ T cells in patients with HTLV-1-associated
neurological disease. J Virol 2003, 77:9716-9722.
5. Toulza F, Heaps A, Tanaka Y, Taylor GP, Bangham CR: High frequency of
CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-
specific CTL response. Blood 2008, 111:5047-5053.
6. Yu F, Itoyama Y, Fujihara K, Goto I: Natural killer (NK) cells in HTLV-Iassociated
myelopathy/tropical spastic paraparesis-decrease in NK cell
subset populations and activity in HTLV-I seropositive individuals. J
Neuroimmunol 1991, 33:121-128.
7. Saito M, Braud VM, Goon P, Hanon E, Taylor GP, Saito A, Eiraku N, Tanaka Y,
Usuku K, Weber JN, et al: Low frequency of CD94/NKG2A+ T lymphocytes
in patients with HTLV-1-associated myelopathy/tropical spastic
paraparesis, but not in asymptomatic carriers. Blood 2003, 102:577-584.
8. Yamano Y, Cohen CJ, Takenouchi N, Yao K, Tomaru U, Li HC, Reiter Y,
Jacobson S: Increased expression of human T lymphocyte virus type I
(HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen
A*201 complexes on CD4+ CD25+ T Cells detected by peptide-specific,
major histocompatibility complex-restricted antibodies in patients with
HTLV-I-associated neurologic disease. J Exp Med 2004, 199:1367-1377.
9. Yamano Y, Nagai M, Brennan M, Mora CA, Soldan SS, Tomaru U,
Takenouchi N, Izumo S, Osame M, Jacobson S: Correlation of human T-cell
lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virusspecific
CD8(+) T cells, and disease severity in HTLV-1-associated
myelopathy (HAM/TSP). Blood 2002, 99:88-94.
10. Asquith B, Mosley AJ, Heaps A, Tanaka Y, Taylor GP, McLean AR,
Bangham CR: Quantification of the virus-host interaction in human T
lymphotropic virus I infection. Retrovirology 2005, 2:75.
11. Meekings KN, Leipzig J, Bushman FD, Taylor GP, Bangham CR: HTLV-1
integration into transcriptionally active genomic regions is associated
with proviral expression and with HAM/TSP. PLoS Pathog 2008, 4:
e1000027.
12. Storey J: A direct approach to false discovery rates. J Roy Stat Soc B 2002,
64:479-498.
13. Niederkofler EE, Tubbs KA, Kiernan UA, Nedelkov D, Nelson RW: Novel mass
spectrometric immunoassays for the rapid structural characterization of
plasma apolipoproteins. J Lipid Res 2003, 44:630-639.
14. Sokal RR, J RF: Biometry New York: W. H. Freeman; 2004.
15. Kay NE, Shanafelt TD: Prognostic factors in chronic lymphocytic leukemia.
Curr Hematol Malig Rep 2007, 2:49-55.
16. Swan F, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P,
Hagemeister FB, Cabanillas F: A new serologic staging system for largecell
lymphomas based on initial beta 2-microglobulin and lactate
dehydrogenase levels. J Clin Oncol 1989, 7:1518-1527.
17. Bergsagel PL: Individualizing therapy using molecular markers in multiple
myeloma. Clin Lymphoma Myeloma 2007, 7:S170-174.
18. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV:
The prognostic value of cellular and serologic markers in infection with
human immunodeficiency virus type 1. N Engl J Med 1990, 322:166-172.
19. Leligdowicz A, Feldmann J, Jaye A, Cotten M, Dong T, McMichael A,
Whittle H, Rowland-Jones S: Direct relationship between virus load and
systemic immune activation in HIV-2 infection. J Infect Dis 2010,
201:114-122.
20. Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I,
Andreasen N, Wallin A, Waldemar G, Blennow K: Identification of a novel
panel of cerebrospinal fluid biomarkers for Alzheimer’s disease. Neurobiol
Aging 2008, 29:961-968.
21. Bjerrum OW, Bach FW, Zeeberg I: Increased level of cerebrospinal fluid
beta 2-microglobulin is related to neurologic impairment in multiple
sclerosis. Acta Neurol Scand 1988, 78:72-75.
22. Carrieri PB, Indaco A, Maiorino A, Buscaino GA, Ponticiello A, Liberti A,
Perrella O: Cerebrospinal fluid beta-2-microglobulin in multiple sclerosis
and AIDS dementia complex. Neurol Res 1992, 14:282-283.
23. Ott M, Demisch L, Engelhardt W, Fischer PA: Interleukin-2, soluble
interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin
levels in CSF and serum of patients with relapsing-remitting or chronicprogressive
multiple sclerosis. J Neurol 1993, 241:108-114.
24. Hessian PA, Edgeworth J, Hogg N: MRP-8 and MRP-14, two abundant Ca
(2+)-binding proteins of neutrophils and monocytes. J Leukoc Biol 1993,
53:197-204.
25. Passey RJ, Xu K, Hume DA, Geczy CL: S100A8: emerging functions and
regulation. J Leukoc Biol 1999, 66:549-556.
26. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, Harms E,
Sorg C, Roth J: Myeloid-related proteins 8 and 14 are specifically
secreted during interaction of phagocytes and activated endothelium
and are useful markers for monitoring disease activity in pauciarticularonset
juvenile rheumatoid arthritis. Arthritis Rheum 2000, 43:628-637.
27. Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, Zwadlo G, Gerhards G,
Schlegel R, Sorg C: Two calcium-binding proteins in infiltrate
macrophages of rheumatoid arthritis. Nature 1987, 330:80-82.
28. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H: Increased
macrophage subset in inflammatory bowel disease: apparent
recruitment from peripheral blood monocytes. Gut 1994, 35:669-674.
29. Roth J, Teigelkamp S, Wilke M, Grun L, Tummler B, Sorg C: Complex
pattern of the myelo-monocytic differentiation antigens MRP8 and
MRP14 during chronic airway inflammation. Immunobiology 1992,
186:304-314.
30. Goebeler M, Roth J, Burwinkel F, Vollmer E, Bocker W, Sorg C: Expression
and complex formation of S100-like proteins MRP8 and MRP14 by
macrophages during renal allograft rejection. Transplantation 1994,
58:355-361.
31. Bealer JF, Colgin M: S100A8/A9: a potential new diagnostic aid for acute
appendicitis. Acad Emerg Med 2010, 17:333-336.
32. Iwasaki Y: Human T cell leukemia virus type I infection and chronic
myelopathy. Brain Pathol 1993, 3:1-10.
33. Martin-Campos JM, Escola-Gil JC, Ribas V, Blanco-Vaca F: Apolipoprotein AII,
genetic variation on chromosome 1q21-q24, and disease
susceptibility. Curr Opin Lipidol 2004, 15:247-253.
34. Castellani LW, Navab M, Van Lenten BJ, Hedrick CC, Hama SY, Goto AM,
Fogelman AM, Lusis AJ: Overexpression of apolipoprotein AII in
transgenic mice converts high density lipoproteins to proinflammatory
particles. J Clin Invest 1997, 100:464-474.
35. Thompson PA, Berbee JF, Rensen PC, Kitchens RL: Apolipoprotein A-II
augments monocyte responses to LPS by suppressing the inhibitory
activity of LPS-binding protein. Innate Immun 2008, 14:365-374.
36. Semmes OJ, Cazares LH, Ward MD, Qi L, Moody M, Maloney E, Morris J,
Trosset MW, Hisada M, Gygi S, Jacobson S: Discrete serum protein
signatures discriminate between human retrovirus-associated
hematologic and neurologic disease. Leukemia 2005, 19:1229-1238.
37. Churchill GA: Using ANOVA to analyze microarray data. Biotechniques
2004, 37:173-175, 177.
38. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J Roy Stat Soc B 1995,
57:289-300.
39. Friedman J, Hastie T, Tibshirani R: Regularization paths for generalized
linear models via coordinate descent. J Stat Softw 2010, 33:1-22.
40. Tibshirani R: Regression shrinkage and selection via the Lasso. Journal of
the Royal Statistical Society Series B-Methodological 1996, 58:267-288.
41. Saeys Y, Abeel T, Van de Peer Y: Robust feature selection using ensemble
feature selection techniques. In Lecture Notes in Computer Science. Volume
5212. Berlin/Heidelberg: Springer; 2008:313-325.
42. Wait R, Miller I, Eberini I, Cairoli F, Veronesi C, Battocchio M, Gemeiner M,
Gianazza E: Strategies for proteomics with incompletely characterized
genomes: the proteome of Bos taurus serum. Electrophoresis 2002,
23:3418-3427.
43. Searle BC: Scaffold: a bioinformatic tool for validating MS/MS-based
proteomic studies. Proteomics 2010, 10:1265-1269.